GMAB250516P25000
- 7.80
- 0.000.00%
Genmab Newsroom
William Blair Maintains Genmab(GMAB.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Envista Holdings (NVST)
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $37
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Genmab's Strong Market Position and Growth Potential Justifies Buy Rating
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Geron (GERN), Genmab (GMAB) and Elanco Animal Health (ELAN)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Genmab Analyst Ratings
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $37
Genmab's Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25